Trent Richards, MD
Ophthalmology · Layton, UTNPI 1184923807
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Oyster Point Pharma, Inc. at 32.0% of the total. Reporting peaked in 2022 at $700 and has fallen 88.9% since, to $78 in 2025.
Across 101 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$585
- Sun Pharmaceutical Industries Inc.$259
- Heru, Inc.$214
- Novartis$126
- AbbVie$116
- Kala Pharmaceuticals, Inc.$96
- plus $433 from 12 others
Across 9 payments — averaging $2772.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kala Pharmaceuticals, Inc.$25K
What the payments were for
- Food & beverage$1,79098%
- Gifts$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 43 | $585 |
| Sun Pharmaceutical Industries Inc. | 13 | $259 |
| Heru, Inc. | 2 | $214 |
| Novartis | 9 | $126 |
| AbbVie(2 entities) | 5 | $116 |
| Kala Pharmaceuticals, Inc. | 5 | $96 |
| Alcon | 4 | $92 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $50 |
| Sight Sciences, Inc. | 3 | $43 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Rxsight Inc | 2 | $35 |
| Biotissue Holdings Inc. | 2 | $34 |
| Amgen | 2 | $30 |
| Bausch & Lomb Americas Inc. | 2 | $28 |
| Glaukos Corporation | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Dompe US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Heru HMD$150
How this compares
$1,829 in reported general payments places this provider in the 65th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 96 | $85,032 |
| XiidraLifitegrast | 21 | $19,340 |
| Prednisolone Acetate | 434 | $12,975 |
| Cyclosporine | 28 | $8,088 |
| MoxifloxacinMoxifloxacin Hcl | 294 | $7,592 |
| LumiganBimatoprost | 15 | $5,379 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,214 |
| ValacyclovirValacyclovir Hcl | 23 | $2,267 |
| Ketorolac Tromethamine | 84 | $2,037 |
| Latanoprost | 207 | $1,755 |
| Doxycycline Monohydrate | 32 | $1,087 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $979 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $892 |
| Timolol Maleate | 42 | $528 |
| Dorzolamide Hcl | 14 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $116 | $90,411111 claims |
| Bausch & Lomb Americas Inc.Xiidra | $28 | $19,34021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Layton
- Robert TreftLayton$4K
- Mark HillLayton$4K
- Jared PetersonLayton$3K
- Nathan LawLayton$2K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.